Histiocytic Disorders, Malignant clinical trials at UCSF

1 research study open to eligible people

Histiocytic disorders, malignant are rare diseases where certain immune cells grow uncontrollably. UCSF is conducting a study about cobimetinib, a drug used in people with Langerhans cell histiocytosis to see if it helps control the disease. This trial includes both children and adults with these histiocytic conditions.

Showing trials for

  • Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

    open to all eligible people

    This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients will be enrolled.

    San Francisco, California and other locations

Last updated: